Proteasome as an Emerging Therapeutic Target in Cancer

Author(s): I. Zavrski, L. Kleeberg, M. Kaiser, C. Fleissner, U. Heider, J. Sterz, C. Jakob, O. Sezer.

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 5 , 2007

Submit Manuscript
Submit Proposal

Abstract:

The 26S proteasome is a multicatalytic intracellular protease expressed in eukaryotic cells. It is responsible for selective degradation of intracellular proteins that are responsible for cell proliferation, growth, regulation of apoptosis and transcription of genes involved in execution of key cellular functions. Thus proteasome inhibition is a potential treatment option for cancer and diseases due to aberrant inflammation condition. Treatment with proteasome inhibitors results in stabilization and accumulation proteasome substrates, a phenomenon that may result in confounding signals in cells, cell cycle arrest and activation of apoptotic programs. The inhibition of the transcriptional factor nuclear factor κB (NF- κB) activation was found as one of crucial mechanisms in induction of apoptosis, overcoming resistance mechanisms and inhibition of immune response and inflammation mechanisms. Bortezomib (PS-341) and PS-519 are the first proteasome inhibitors that have entered clinical trials. In multiple myeloma, both the FDA (United States Food and Drug Administration) and EMEA (European Medicine Evaluation Agency) granted an approval for the use of bortezomib (Velcade®) for the treatment of relapsed multiple myeloma. At present, several phase II and phase III trials in hematological malignancies and solid tumors are ongoing. PS-519 that focuses on inflammation, reperfusion injury and ischemia is currently under evaluation for the indication of acute stroke.

Keywords: Proteasome, bortezomib, PS-519, cancer, myeloma, lymphoma, inflammation

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 5
Year: 2007
Page: [471 - 485]
Pages: 15
DOI: 10.2174/138161207780162908
Price: $58